Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Treatments: Bevacizumab; Cetuximab

Criteria

Inclusion Criteria:

• BE patients without dysplasia and with suspected/diagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and/or therapeutic endoscopy

• Written informed consent is obtained

Exclusion Criteria:

• Patients under the age of eighteen.

• Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.

• Previous radiation therapy for esophageal cancer

• Known immunoglobulin allergy

• Previous chemotherapy, immunotherapy or related surgery

• Prior bevacizumab or cetuximab treatment

• Medical or psychiatric conditions that compromise the patient's ability to give informed consent

• Pregnancy or breast feeding.